Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises

Fate Therapeutics

13/08/2026 13:38

Overview
US biopharmaceutical firm's Q2 collaboration revenue rose modestly yr/yr
Net loss for Q2 narrowed compared to prior yr, driven by lower operating expenses

Outlook
Company aims to complete RECLAIM-LN trial enrollment in first half of 2028
Fate expects to provide FT839 enrollment update later in 2026
Company expects FT836 clinical update in first half of 2027
Company projects cash runway into 2028

Result Drivers
CLINICAL MILESTONES - Co dosed first lupus nephritis patient in Phase 2 trial with FT819 and advanced FT839 into Phase 1/2 trial after FDA clearance
EXPENSE REDUCTION - Lower research and administrative expenses contributed to a narrower net loss

Company press release: ID:nGNX2R8GzG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$2.08 mln
 
Q2 Net Loss
 
$30.16 mln
 
Q2 Income from Operations
 
-$31.13 mln
 
Q2 Loss Per Basic Share
 
$0.25
 
Q2 Operating Expenses
 
$33.22 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.50, about 139% above its August 12 closing price of $2.72

Reuters Recommended Reads
Aug 13 - Cabaletta Bio Q2 net loss widens as R&D costs rise
Aug 13 - MiNK Therapeutics Q2 loss narrows on expense discipline
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)